Peter S. LaViolette

Name: dblp XML data dump
Creator: Schloss Dagstuhl - Leibniz Center for Informatics
Published: 1993
License: https://creativecommons.org/publicdomain/zero/1.0/
Keywords: dblp, XML, computer science, scholarly publications, metadata

◀ ▶ joint publications with Anant Madabhushi

> Home > Persons > Peter S. LaViolette

Publications

2022
[j4]
- view
  - electronic edition via DOI (open access)
  - details & citations
  authority control:
- export record
  dblp key:
  - journals/tmi/IsmailPBSHSPBML22
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/journals/tmi/IsmailPBSHSPBML22
Marwa Ismail, Prateek Prasanna, Kaustav Bera, Volodymyr Statsevych, Virginia B. Hill, Gagandeep Singh, Sasan Partovi, Niha G. Beig, Sean D. McGarry, Peter S. LaViolette, Manmeet Ahluwalia, Anant Madabhushi, Pallavi Tiwari:
Radiomic Deformation and Textural Heterogeneity (R-DepTH) Descriptor to Characterize Tumor Field Effect: Application to Survival Prediction in Glioblastoma. IEEE Trans. Medical Imaging 41(7): 1764-1777 (2022)
2021
[i2]
- view
  - electronic edition @ arxiv.org (open access)
  - details & citations
- export record
  dblp key:
  - journals/corr/abs-2103-07423
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/journals/corr/abs-2103-07423
Marwa Ismail, Prateek Prasanna, Kaustav Bera, Volodymyr Statsevych, Virginia B. Hill, Gagandeep Singh, Sasan Partovi, Niha G. Beig, Sean D. McGarry, Peter S. LaViolette, Manmeet Ahluwalia, Anant Madabhushi, Pallavi Tiwari:
Radiomic Deformation and Textural Heterogeneity (R-DepTH) Descriptor to characterize Tumor Field Effect: Application to Survival Prediction in Glioblastoma. CoRR abs/2103.07423 (2021)

manage site settings

To protect your privacy, all features that rely on external API calls from your browser are turned off by default. You need to opt-in for them to become active. All settings here will be stored as cookies with your web browser. For more information see our F.A.Q.